Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, No 1, Youyi Road, Yuzhong District, Chongqing, 400016, China.
Department of General Practice, University of Chinese Academy of Sciences Chongqing Hospital, Chongqing, China.
BMC Cancer. 2021 May 25;21(1):603. doi: 10.1186/s12885-021-08086-y.
Almost one-third of patients with diffuse large B-cell lymphoma (DLBCL) cannot be cured with initial therapy and will eventually succumb to the disease. Further elaboration of prognostic markers of DLBCL will provide therapeutic targets. IQ motif-containing GTPase activating protein 2 (IQGAP2) acts as a tumour suppressor in hepatocellular, prostate, and gastric cancers. However, the role of IQGAP2 in DLBCL remains unclear.
We collected mRNA expression data from 614 samples and the corresponding clinical information. The survival time of patients was compared between groups according to the mRNA expression level of IQGAP2. Survival analyses were performed in different subgroups when considering the effect of age, tumour stage, serum lactate dehydrogenase (LDH) concentration, performance status, and the number of extra nodal disease sites. The biological processes associated with IQGAP2-associated mRNAs were analysed to predict the function of IQGAP2. The correlation of IQGAP2 mRNA with immunosuppressive genes and leukocyte infiltration were analysed.
The overall survival of patients with increased IQGAP2 mRNA levels was reduced even after aggressive treatment independent of age, tumour stage, serum LDH concentration, performance status, and the number of extra nodal disease sites. Furthermore, the biological processes of IQGAP2-associated mRNAs were mainly immune processes. IQGAP2 mRNA expression was correlated with the expression of immunosuppressive genes and leukocyte infiltration.
IQGAP2 mRNA is an independent prognostic factor and is related to immunosuppression in DLBCL. This discovery may provide a promising target for further development of therapy.
大约三分之一的弥漫性大 B 细胞淋巴瘤（DLBCL）患者不能通过初始治疗治愈，最终将死于该疾病。进一步阐述 DLBCL 的预后标志物将为治疗提供目标。IQ 基序富含 GTP 酶激活蛋白 2（IQGAP2）在肝癌、前列腺癌和胃癌中作为肿瘤抑制因子发挥作用。然而，IQGAP2 在 DLBCL 中的作用尚不清楚。
我们收集了 614 个样本的 mRNA 表达数据和相应的临床信息。根据 IQGAP2 的 mRNA 表达水平，比较了患者组之间的生存时间。当考虑年龄、肿瘤分期、血清乳酸脱氢酶（LDH）浓度、表现状态和结外疾病部位数量的影响时，在不同亚组中进行了生存分析。分析与 IQGAP2 相关的 mRNA 相关的生物学过程，以预测 IQGAP2 的功能。分析 IQGAP2 mRNA 与免疫抑制基因和白细胞浸润的相关性。
即使在积极治疗后，IQGAP2 mRNA 水平升高的患者的总生存率仍然降低，而与年龄、肿瘤分期、血清 LDH 浓度、表现状态和结外疾病部位数量无关。此外，IQGAP2 相关 mRNA 的生物学过程主要是免疫过程。IQGAP2 mRNA 表达与免疫抑制基因的表达和白细胞浸润相关。
IQGAP2 mRNA 是一个独立的预后因素，与 DLBCL 中的免疫抑制有关。这一发现可能为进一步开发治疗方法提供一个有前途的靶点。
